Tazemetostat Hydrobromide

CAS 1467052-75-0 0 current recordsSmall Molecule

Who holds supplier records for Tazemetostat Hydrobromide? No organisation holds a current US Type II DMF or EU CEP for Tazemetostat Hydrobromide in the registers PharmaTek covers.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Tazemetostat Hydrobromide: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/tazemetostat-hydrobromide

Reading the evidence

  • No current DMF or CEP on record

    The covered registers hold no supplier record for this substance. This is not evidence that no one makes it: suppliers may file under another name, sell outside the US and EU, or use an ASMF.

Current records (0)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Tazemetostat Hydrobromide. Country is the organisation's recorded country, not necessarily the manufacturing site.

Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.

Need Tazemetostat Hydrobromide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Overview

Tazemetostat Hydrobromide is a small molecule inhibitor of the EZH2 methyltransferase, which is involved in the regulation of gene expression through histone modification. It is primarily used in the treatment of certain types of cancers, including epithelioid sarcoma.

Chemical identity

IUPAC name
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide
Canonical SMILES
CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5.Br
InChIKey
UQRICAQPWZSJNF-UHFFFAOYSA-N
Synonyms
Tazverik API, e-7438 hydrobromide, epz-6438 monohydrobromide, ez-438, ez438, tazemetostat monohydrobromide, tazverik

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Methyltransferase Inhibitor
Mechanism of action
Methyltransferase Inhibitors; Multidrug and Toxin Extrusion Transporter 1 Inhibitors; Multidrug and Toxin Extrusion Transporter 2 K Inhibitors

Therapeutic areas

Oncology

Record history

PharmaTek records which organisations hold a current DMF or CEP for Tazemetostat Hydrobromide every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.
For suppliers

Do you supply Tazemetostat Hydrobromide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.